[Implications of receptors for the Fc portion of IgG (FcgammaRs) in mechanism of action of therapeutic antibodies].
From several years ago, recombinant monoclonal antibodies have allowed a revolution in therapeutic approach of cancer patients. Whereas the clinical efficacy of many antibodies is now demonstrated, their mechanism of action in patients remains elusive. For antibodies targeting membrane antigens, they particularly resort to cytotoxic effectors, which expressed receptors for Fc portion of IgG (FcgammaRs). This review analyses different functions depending of FcgammaR and their potential role in mechanism of action of therapeutic antibodies. A better knowledge of these functions should allow in the next future the optimisation of these treatments.
Lejeune
J
J
UMR CNRS 6239, Génétique, Immunothérapie, Chimie et Cancer, 37200 Tours, France.
Thibault
G
G
Cartron
G
G
Ohresser
M
M
Watier
H
H
D000818:Animals; D000911:Antibodies, Monoclonal / Q000276:immunology / Q000494:pharmacology* / Q000627:therapeutic use; D000920:Antibody-Dependent Cell Cytotoxicity / Q000276:immunology; D000954:Antigens, Surface / Q000276:immunology; D006801:Humans; D051379:Mice; D009369:Neoplasms / Q000276:immunology / Q000628:therapy*; D011110:Polymorphism, Genetic; D017452:Receptors, IgG / Q000235:genetics / Q000502:physiology*; D011994:Recombinant Proteins / Q000276:immunology / Q000494:pharmacology / Q000627:therapeutic use
D000911:Antibodies, Monoclonal; D000954:Antigens, Surface; D017452:Receptors, IgG; D011994:Recombinant Proteins